The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.
An article from
News roundup
The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.
Published May 18, 2026
Getty Images
FDA shuffles top drug, biologics leaders in latest shakeup
AstraZeneca picks up FDA approval for hypertension drug
FDA floats possible approach to repurpose approved drugs under new uses
Regulatory round-up: A month of key FDA approvals for cancer drugs - Pharmaceutical Technology
After Makary departure, CDER chief Tracy Beth Høeg likely headed out at FDA: report
BeOne wins FDA approval in lymphoma race
Supreme Court declines to hear IRA challenges from Novo, AZ and more
The Oral GLP-1 Tracker: Wegovy pill total scripts down for first time
Amgen stands by Tavneos, despite reports of 20 deaths in Japan
FDA seeks to withdraw avacopan approval over alleged data manipulation, false statements
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its…
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
The U.S. Food and Drug Administration is shuffling its top drug and biologics regulators, days after the departure of former…
The China question, FDA leadership shakeups, and other biotech news from The Readout
The FDA is looking to get thrifty with its approved drugs. | The framework would leverage existing safety data on approved drugs…
